incretina glp 1 Incretins as Multi–Disease State Treatments Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic

For people without pre-existing heart conditions, investing in these therapies still proves economically viable according to cardiovascular outcome trialsas shown by their favorable quality-adjusted life year (QALY) figureswhich underscores the broader value of GLP-1 agonists in improving cardiovascular outcomes

Injections may be recommended if absorption is a concern

For people using unregulated products, the most frequent complaints line up with general injection or GIrelated issues: Injectionsite pain, swelling, or redness

Presented for research literature review only Kyrillos JV et al

Additionally, these drugs are generally well tolerated